Salidroside Activates the AMP‐Activated Protein Kinase Pathway to Suppress Nonalcoholic Steatohepatitis in Mice
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Background and Aims: NASH is becoming a leading cause of liver cirrhosis and HCC. Salidroside (p‐hydroxyphenethyl‐β‐D‐glucoside; SAL) has various biological and pharmacological activities, including anti‐inflammatory, ‐oxidant, and ‐cancer activities. However, the therapeutic effect and underlying molecular mechanism of SAL in NASH remain to be further clarified. Methods and Results: In this study, we found that SAL alleviated lipid accumulation and inflammatory response in primary hepatocytes after palmitic acid/oleic acid (PO) stimulation. In addition, SAL effectively prevented high‐fat/high‐cholesterol (HFHC)‐diet–induced NASH progression by regulating glucose metabolism dysregulation, insulin resistance, lipid accumulation, inflammation, and fibrosis. Mechanistically, integrated RNA‐sequencing and bioinformatic analysis showed that SAL promoted AMPK‐signaling pathway activation in vitro and in vivo, and this finding was further verified by determining the phosphorylation levels of AMPK. Furthermore, the protective effects of SAL on lipid accumulation and inflammation in hepatocytes and livers induced by PO or HFHC stimulation were blocked by AMPK interruption. Conclusions: Our studies demonstrate that SAL protects against metabolic‐stress–induced NASH progression through activation of AMPK signaling, indicating that SAL could be a potential drug component for NASH therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
AMPK signalling in health and disease
Carling, D. (2017) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2017.01.005 · Cited by 797
The Role of Innate Immune Cells in Nonalcoholic Steatohepatitis
Cai, J., Zhang, X., & Li, H. (2019) · Hepatology · doi:10.1002/hep.30506 · Cited by 207
Cited by
Metabolic reprogramming in liver fibrosis
Horn, P., & Tacke, F. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.05.003 · Cited by 432
Cao, X., Fang, W., Li, X., Wang, X., Mai, K., & Ai, Q. (2022) · iScience · doi:10.1016/j.isci.2022.104670 · Cited by 32
Self-citationSalidroside suppresses proliferation and migration in prostate cancer via the PI3K/AKT pathway
Liu, R.-H., Ma, T.-F., Yang, Q., Xiao, W.-C., Yin, L., Yin, M., Zhang, J.-S., & Wang, C.-H. (2023) · Cancer Biomarkers · doi:10.3233/cbm-220454 · Cited by 14
Metadata
- Authors
- Hu, M., Zhang, D., Xu, H., Zhang, Y., Shi, H., Huang, X., Wang, X., Wu, Y., & Qi, Z.
- Venue
- Hepatology
- Published
- 2021-10-21
- Volume
- 74
- Issue
- 6
- Pages
- 3056-3073
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W3184800199
- Cited by
- 93
- References
- 4
- FWCI
- 8.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Salidroside Activates the AMP‐Activated Protein Kinase Pathway to Suppress Nonalcoholic Steatohepatitis in Mice. https://app.cochat.ai/papers/10.1002/hep.32066
- The paper
- Hu, M., Zhang, D., Xu, H., Zhang, Y., Shi, H., Huang, X., Wang, X., Wu, Y., & Qi, Z. (2021). Salidroside Activates the AMP‐Activated Protein Kinase Pathway to Suppress Nonalcoholic Steatohepatitis in Mice. Hepatology. https://doi.org/10.1002/hep.32066
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.